Journal Article

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

Menarguez, Javier, Bonzheim, Irina, Lutz, Mathias, Chapuy, Björn, Salar, Antonio, Mate, José Luis, Grau, Michael, Tzankov, Alexandar, Zapukhlyak, Myroslav, Heming, Jan-Niklas, Castellvi, Josep, Rosenwald, Andreas, Dirnhofer, Stefan, Navarro, José-Tomas, Ehrenfeld, Sophia, Xu, Wendan, Wienand, Kirsty, Lamping, Mario, Anagnostopoulos, Ioannis, Aldamiz, Teresa, Tapia, Gustavo, Miething, Cornelius, Veratti, Pia, Richter, Julia, Frontzek, Fabian, Klapper, Wolfram, Lenz, Peter, Baptista, Maria Joao, Wilson, Matthew R., Goodlad, John R., Ott, German, Erdmann, Tabea, Staiger, Annette M., Berning, Philipp, Abrisqueta, Pau, Sander, Philip, Climent, Fina, Lenz, Georg, Horn, Heike, Gonzalez-Barca, Eva, Borgmann, Vanessa, Fend, Falko, Hartmann, Wolfgang, Wullenkord, Ramona

2021

Overview

Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited. A hallmark of PBL represents its plasmacytic differentiation with loss of B-cell markers and, in 60% of cases, its association with Epstein-Barr virus (EBV). Roughly 50% of PBLs harbor a MYC translocation. Here, we provide a comprehensive integrated genomic analysis using whole exome sequencing (WES) and genome-wide copy number determination in a large cohort of 96 primary PBL samples. We identify alterations activating the RAS-RAF, JAK-STAT, and NOTCH pathways as well as frequent high-level amplifications in MCL1 and IRF4 . The functional impact of these alterations is assessed using an unbiased shRNA screen in a PBL model. These analyses identify the IRF4 and JAK-STAT pathways as promising molecular targets to improve outcome of PBL patients. Plasmablastic lymphoma (PBL) is an aggressive lymphoma subtype characterized by poor prognosis but the molecular knowledge of the disease is limited. Here, the authors perform whole exome sequencing and copy number determination of primary samples highlighting IRF4 and JAK-STAT pathways as therapeutic targets for PBL.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 13/89 / 14/1 / 14/32 / 45 / 45/23 / 631/67/68 / 692/4028/67/1990/291/1621/1915 / 82/51 / 96/1 / 96/106 / 96/31 / 96/98 / Cell differentiation / Copy number / Epstein-Barr virus / Gene sequencing / Genomic analysis / Humanities and Social Sciences / Immunosuppression / Interferon regulatory factor 4 / Lymphocytes B / Lymphoma / Mcl-1 protein / multidisciplinary / Myc protein / Pathogenesis / Science / Science (multidisciplinary) / Therapeutic targets / Translocation